Literature DB >> 19619754

Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5.

Sam Mehr1, Sylvan Rego, Alyson Kakakios, Henry Kilham, Andrew Kemp.   

Abstract

We report the use of anti-interleukin-5 (mepolizumab) during an 18-month period in a pediatric hypereosinophilic syndrome. Infusions every 3 months allowed better control of hypereosinophilic syndrome flares and maintained blood eosinopenia with significantly less steroid use compared with all other therapies (prednisolone alone, interferon alpha, or imatinib mesylate).

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19619754     DOI： 10.1016/j.jpeds.2009.01.058

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


  4 in total

Review 1.  An Overview of Off-Label Use of Humanized Monoclonal Antibodies in Paediatrics.

Authors:  Roberto Bernardini; Gaia Toschi Vespasiani; Arianna Giannetti
Journal:  Medicina (Kaunas)       Date:  2022-04-29       Impact factor: 2.948

Review 2.  Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.

Authors:  Ayalew Tefferi; Jason Gotlib; Animesh Pardanani
Journal:  Mayo Clin Proc       Date:  2010-01-06       Impact factor: 7.616

Review 3.  A new look at the pathogenesis of asthma.

Authors:  Stephen T Holgate; Hasan S Arshad; Graham C Roberts; Peter H Howarth; Philipp Thurner; Donna E Davies
Journal:  Clin Sci (Lond)       Date:  2009-12-23       Impact factor: 6.124

Review 4.  Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma.

Authors:  Florence Roufosse
Journal:  Front Med (Lausanne)       Date:  2018-04-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.